Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
- 11 June 1994
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 343 (8911) , 1460-1463
- https://doi.org/10.1016/s0140-6736(94)92581-x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Induction and Enhancement of Immune Responses to Herpes Simplex Virus Type 2 in Humans by Use of a Recombinant Glycoprotein D VaccineThe Journal of Infectious Diseases, 1993
- A Phase I Evaluation of the Safety and Immunogenicity of Vaccination with Recombinant gp160 in Patients with Early Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1991
- Preinfection Prophylaxis with Herpes Simplex Virus Glycoprotein Immunogens: Factors Influencing EfficacyJournal of General Virology, 1989
- A Seroepidemiologic Survey of the Prevalence of Herpes Simplex Virus Type 2 Infection in the United StatesNew England Journal of Medicine, 1989
- Herpes Simplex Virus Glycoprotein Treatment of Recurrent Genital HerpesThe Journal of Infectious Diseases, 1988
- Vaccination with Recombinant Herpes Simplex Virus Glycoproteins: Protection Against Initial and Recurrent Genital HerpesThe Journal of Infectious Diseases, 1987
- Herpes Simplex Virus Type-2 Glycoprotein-Subunit Vaccine: Tolerance and Humoral and Cellular Responses in HumansThe Journal of Infectious Diseases, 1984
- A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus InfectionNew England Journal of Medicine, 1984
- Suppression of Frequently Recurring Genital HerpesNew England Journal of Medicine, 1984
- Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trialJAMA, 1984